Lacidipine
Brand names: Motens
Lacidipine is a dihydropyridine calcium-channel blocker used in the treatment of hypertension.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It selectively blocks L-type calcium channels in vascular smooth muscle, causing arterial vasodilatation that reduces peripheral vascular resistance and lowers blood pressure.
Prescribing in practice
- Vasodilatory effects such as ankle oedema, flushing, headache and palpitations are common and may limit treatment.
- Use with caution in significant hepatic impairment, which can increase exposure to the drug.
- It is contraindicated in patients with hypersensitivity to dihydropyridines, and caution is needed in unstable or significant aortic stenosis.
Monitoring
Monitor blood pressure for response and review the patient for dose-related ankle swelling and other vasodilatory effects.
Counselling the patient
- Ankle swelling, flushing or headache may occur, particularly early in treatment.
- Report palpitations or significant dizziness.
- Continue taking the medicine regularly even when you feel well, as it controls rather than cures high blood pressure.
Evidence & guidelines
Dihydropyridine calcium-channel blockers are a recommended class for hypertension in NICE guidance, with established blood-pressure-lowering efficacy.
Reference: NICE NG136; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines